FY2025 EPS Forecast for Arbutus Biopharma Reduced by Analyst
Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) – Equities research analysts at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for shares of Arbutus Biopharma in a report issued on Tuesday, March 4th. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($0.38) per share for the year, down […]
Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) – Equities research analysts at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for shares of Arbutus Biopharma in a report issued on Tuesday, March 4th. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($0.38) per share for the year, down […]
